- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:26 | OS Therapies: OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes | 229 | Newsfile | New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference... ► Artikel lesen | |
| Mo | OS Therapies: OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor | 688 | Newsfile | Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria... ► Artikel lesen | |
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 08.04. | OS Therapies: OS Therapies Appoints Craig Eagle, MD as Strategic Advisor | 997 | Newsfile | Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma regulatory advice and oncology... ► Artikel lesen | |
| 02.04. | OS Therapies: OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors | 708 | Newsfile | Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26Company expects to receive approximately $2 million in non-dilutive R&D tax credits... ► Artikel lesen | |
| 31.03. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OS Therapies: OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update | 315 | Newsfile | December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval PathwayPre-specified clinical outcomes... ► Artikel lesen | |
| 27.03. | OS Therapies: OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma | 323 | Newsfile | Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in Australia Commencing the... ► Artikel lesen | |
| 25.03. | OS Therapies: OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma | 388 | Newsfile | ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for small and medium-sized enterprises (SMEs)... ► Artikel lesen | |
| 09.03. | OS Therapies: OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting | 374 | Newsfile | FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New... ► Artikel lesen | |
| 06.03. | OS Therapies Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings | 1 | Benzinga.com | ||
| 17.02. | OS Therapies: OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma | 446 | Newsfile | Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomesU.S., U.K. and European osteosarcoma key... ► Artikel lesen | |
| 13.02. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | OS Therapies: OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies | 457 | Newsfile | New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is... ► Artikel lesen | |
| 02.02. | OS Therapies: OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 456 | Newsfile | Request for FDA Rolling Review submitted to FDA on January 30, 2026Non-Clinical and CMC BLA modules submitted to FDAAt FDA's request, Type D Meeting expected in March 2026 to review Comparative... ► Artikel lesen | |
| 15.01. | OS Therapies Bone Cancer Trial Data Strengthens FDA Case | 3 | Benzinga.com | ||
| 15.01. | OS Therapies: OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | 199 | Newsfile | Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from short-term survivors (Pre-specified pathway analysis strategy developed as... ► Artikel lesen | |
| 14.01. | OS Therapies: OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary | 488 | Newsfile | OS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first... ► Artikel lesen | |
| 12.01. | OS Therapies: OS Therapies Enters into Warrant Inducement Agreements | 264 | Newsfile | $7.53M gross proceeds raised from pre-existing investors, providing capital runway into 2027All nine investors that were offered agreed to participateNet proceeds to fund OST-HER2 regulatory approval... ► Artikel lesen | |
| 12.01. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 47,100 | -2,13 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| IMMUNIC | 0,878 | -6,20 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Medical Conferences in April | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Medical Conferences in April
09.04.2026 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,280 | -3,03 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 | Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,535 | -0,99 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 2,897 | +5,65 % | ANAVEX LIFE SCIENCES CORP: Struktur vor Bewegung | ||
| ZEVRA THERAPEUTICS | 8,600 | -1,83 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,932 | -2,33 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio®... ► Artikel lesen | |
| GEOVAX LABS | 1,300 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax Reports 2025 Year-End Financial Results and Provides Business Update | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Reports 2025 Year-End Financial Results and Provides Business Update 15.04.2026 / 22:13 CET/CEST
The issuer is solely... ► Artikel lesen | |
| SCILEX | 5,100 | -3,77 % | Scilex Holding Co - 10-K, Annual Report | ||
| INVIVYD | 1,665 | -2,35 % | Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles | Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support... ► Artikel lesen | |
| MEIRAGTX | 8,200 | -14,14 % | MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) | Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,736 | -3,21 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen | |
| UNICYCIVE THERAPEUTICS | 6,910 | -0,86 % | Unicycive Therapeutics, Inc.: Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update | Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June... ► Artikel lesen | |
| QIAGEN | 35,000 | -1,71 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| EVOTEC | 5,520 | -0,36 % | Evotec: Kursziel bestätigt - Neue Chancen für Anleger? |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.